In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility

被引：26
作者：
Cota, Jason [1 ]
Carden, Michael [1 ]
Graybill, John R. [1 ]
Najvar, Laura K. [1 ]
Burgess, David S. [1 ]
Wiederhold, Nathan P. [1 ]
机构：
[1] UTHSCSA, Austin Coll Pharm, Clin Pharm, San Antonio, TX 78229 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 11期
关键词：
D O I：
10.1128/AAC.00538-06
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The activities of anidulafungin and caspofungin against Candida glabrata were evaluated. MICs, 50% inhibitory concentrations (IC50 values), and IC90 values for anidulafungin were lower than those for caspofungin for 16 of 18 strains tested. Anidulafungin has potent in vitro activity against C. glabrata that is maintained against isolates with elevated caspofungin MICs.
引用
收藏
页码：3926 / 3928
页数：3
相关论文
共 30 条
  • [1] [Anonymous], 2002, M27A2 CLSI
  • [2] Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens:: a comparative study with M27-A microdilution method
    Arévalo, MP
    Carrillo-Muñoz, AJ
    Salgado, J
    Cardenes, D
    Brió, S
    Quindós, G
    Espinel-Ingroff, A
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) : 163 - 166
  • [3] The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer
    Bodey, GP
    Mardani, M
    Hanna, HA
    Boktour, M
    Abbas, J
    Girgawy, E
    Hachem, RY
    Kontoyiannis, DP
    Raad, II
    [J]. AMERICAN JOURNAL OF MEDICINE, 2002, 112 (05) : 380 - 385
  • [4] Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine
    Dowell, JA
    Stogniew, M
    Krause, D
    Henkel, T
    Weston, IE
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (02) : 227 - 233
  • [5] Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal
    Dowell, JA
    Knebel, W
    Ludden, T
    Stogniew, M
    Krause, D
    Henkel, T
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (06) : 590 - 598
  • [6] Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
    Espinel-Ingroff, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) : 2950 - 2956
  • [7] Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy
    Hakki, Morgan
    Staab, Janet F.
    Marr, Meren A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (07) : 2522 - 2524
  • [8] Caspofungin resistance in Candida albicans:: Correlating clinical outcome with laboratory susceptibility testing of three is genic isolates serially obtained from a patient with progressive candida esophagitis
    Hernandez, S
    López-Ribot, JL
    Najvar, LK
    McCarthy, DI
    Bocanegra, R
    Graybill, JR
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) : 1382 - 1383
  • [9] Influence of test conditions on antifungal time-kill curve results: Proposal for standardized methods
    Klepser, ME
    Ernst, EJ
    Lewis, RE
    Ernst, ME
    Pfaller, MA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) : 1207 - 1212
  • [10] Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient
    Krogh-Madsen, M
    Arendrup, MC
    Heslet, L
    Knudsen, JD
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 42 (07) : 938 - 944
123